 This pilot study will recruit 40 patients with Major Depression and a history of at least two failed prior adequate somatic treatments. In addition to usual physical work-up, all patients will have extensive thyroid testing, and then will receive standard dose Tranylcypromine i.e., max. 60 mgd. Non-remitters will have dose increased to max. 120 mgd if tolerated. Non-remitters to high dose Tranylcypromine will then have Dextroamphetamine added with frequent blood pressure monitoring to max. 40 mgd. Non-remitters will have Triiodothyronine added to the Tranylcypromine. 